Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin

Biberoglu K, K Biberoglu, K. Biberoğlu, Koray Gürsoy, R Gursoy, Gursoy R, Yildiz A, A Yildiz, Abdülkerim Yıldız
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 1991 · vol. 5(2) , pp. 109–122 · doi:10.3109/09513599109028434 · PMID:1833953 · W2158177774
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Buserelin treatment reduced endometriosis pelvic scores and uterine leiomyoma size in women, despite frequent hot flashes, with no dropouts.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The authors examined the effect and tolerability of buserelin in 40 women with endometriosis and ten women with uterine leiomyoma. Buserelin was given intranasally, 200 micrograms three times a day for 6 months. Laparoscopy was performed before and after, and ultrasonography during the treatment. Hormone and lipid profiles and other biochemical tests were run during the treatment. The bone mineral density was tested by dual photon absorptiometry before and after therapy in a group of patients. Although most of the patients complained of hot flushes, no women dropped out. AFS mean pelvic score decreased from 24.10 to 6.95 and the size of the fibroids decreased by 69% at the end of 6 months of treatment. In conclusion, our data suggest that the use of GnRH agonist has a place in the treatment of endometriosis and uterine leiomyoma but further studies are needed to conclude that buserelin given intranasally at a dose of 600 micrograms/day for 6 months is an alternative to other conventional medical treatment modalities in terms of pregnancy and recurrence rates.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Leiomyoma Uterine Neoplasms Administration, Intranasal Adult Alanine Transaminase Alanine Transaminase Aspartate Aminotransferases Aspartate Aminotransferases Bilirubin Bilirubin Blood Glucose Blood Glucose Blood Proteins Blood Proteins Blood Urea Nitrogen Bone Density Bone Density Buserelin

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-31T06:09:41.840111+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:00.397535+00:00
License: CC0 · commercial use OK